Conflicting results from anti-TNF trials in sepsis patients suggest that timely administration of TNF inhibitor drugs is crucial.
References
- 1
Heumann D. & Glauser M.P. Pathogenesis of sepsis. Sci. Am. Med. 1, 28–37 (1994).
- 2
Dellinger, R.P. et al. From the bench to the bedside: The future of sepsis research. Chest 111, 744–753 (1997).
- 3
Abraham E. et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277, 1531–1538 (1997).
- 4
Van Zee K.J. et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-lg fusion protein, Ro 45-2081. J. Immunol. 156, 2221–2230 (1996).
- 5
Cohen, J., Heumann D. & Glauser M.P. Do monoclonal antibodies and anticytokines still have a future in infectious diseases. Am. J. Med. 99, 45S–52S (1995).
- 6
Lesslauer, W. et al. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality. Eur. J. Immunol. 21, 2883–2886 (1991).
- 7
Munoz, C. et al. Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur. J. Immunol. 21, 2177–2184 (1991).
- 8
Andrejko, K.M. & Deutschman, C.S. Acute-phase gene expression correlates with intrahepatic tumor necrosis factor alpha abundance but not with plasma tumor necrosis factor concentrations during sepsis/systemic inflammatory response syndrome in the rat. Crit. Care Med. 24, 1947–1952 (1996).
- 9
Pellegrini, J.D., Puyana, J.C., Lapchak, P.H., Kodys, K. & Millergraziano, C.L. A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 6, 389–396 (1996).
- 10
Wallach, D. A decade of accumulated knowledge and emerging answers. The 6th International Congress on TNF, Rhodes, Greece. May 1996. Eur. Cytokine Netw. 7, 713–724 (1996).
- 11
Vandenabeele, P., Declercq, W., Beyaert, R. & Fiers, W. Two tumor necrosis factor receptors: Structure and function. Tr. Cell Biol. 5, 392–399 (1995).
- 12
Evans, T.J. et al. Protective effect of 55-but not 75kD soluble tumor necrosis factor receptor immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180, 2173–2179 (1994).
- 13
Kwiatkowski, D. et al. Response to monoclonal anti-TNF antibody in children with cerebral malaria. Q. J. Med. 86, 91–98 (1993)
- 14
Brouckaert, P. et al. Inhibition of and sensitization to the lethal effects of tumor necrosis factor. J. Inflamm. 47, 18–26 (1996).
- 15
Döcke, W.D. et al. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment. Nature Med. 3, 678–681 (1997).
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Grau, G., Maennel, D. TNF inhibition and sepsis — sounding a cautionary note. Nat Med 3, 1193–1195 (1997). https://doi.org/10.1038/nm1197-1193
Issue Date:
Further reading
-
ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer
Cell Death & Disease (2021)
-
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Cancers (2019)
-
Pre-existing malignancy results in increased prevalence of distinct populations of CD4+ T cells during sepsis
PLOS ONE (2018)
-
Interleukin-6: designing specific therapeutics for a complex cytokine
Nature Reviews Drug Discovery (2018)
-
Immune therapeutic strategies using optimal controls with L 1 and L 2 type objectives
Mathematical Biosciences (2017)